EGFR family expression in breast carcinomas. c-erbB-2 and c-erbB-4 receptors have different effects on survival
EGFR family expression in breast carcinomas. c-erbB-2 and c-erbB-4 receptors have different effects on survival
复制标题
DOI：
10.1002/path.1003
复制
发表时间：
2002-01-01
影响因子：
7.3
通讯作者：
Nesland, JM
中科院分区：
文献类型：
--
作者：
Suo, Z;Risberg, B;Nesland, JM
采用免疫组化和RT-PCR方法对100例随访7-11年的乳腺癌患者进行EGFR家族成员的研究。通过免疫组织化学，36%、27%、26%和82%的肿瘤EGFR、c-erbB-2、c-erbB-3和c-erbB-4阳性。所有免疫反应性肿瘤经RT-PCR证实均为阳性。在本研究中，肿瘤大小、组织学分级、淋巴结状态、S期分数和分期被证实与无病生存率和癌症特异性生存率显著相关。治疗方法、组织学类型和倍性对生存率没有显著影响。对这些肿瘤中EGFR家族成员的统计分析显示，c-erbB-2表达与无病生存率和癌症特异性生存率降低之间存在显著相关性。c-erbB-4表达与更有利的结局相关。c-erbB-2和EGFR共同表达与预后不良相关。c-erbB-4表达对c-erbB-2表达的临床影响有拮抗作用。总之，c-erbB-2在乳腺癌中的表达与不利的临床过程和EGFR表达具有协同效应。然而，c-erbB-4拮抗c-erbB-2对乳腺癌临床进程的影响。为了达到最佳的结果与c-erbB-2受体的免疫治疗，澄清c-erbB-4表达的状态可能是有意义的。版权所有（C）2001约翰威利父子有限公司
One hundred patients with breast carcinoma followed for 7-11 years were included in the present study of EGFR family members, using inummohistochemistry and RT-PCR. By inummohistochemistry, 36%, 27%, 26%, and 82% of the tumours were positive for EGFR, c-erbB-2, c-erbB-3, and c-erbB4. All the immunoreactive tumours were confirmed positive by RT-PCR. Tumour size, histological grade, lymph node status, S-phase fraction, and stage were confirmed to be significantly associated with both disease-free and cancer-specific survival in the present study. Methods of treatment, histological type, and ploidy had no significant effect on survival. Statistical analysis of EGFR family members in these tumours showed a significant association between c-erbB-2 expression and reduced disease-free and cancer-specific survival. c-erbB-4 expression was associated with a more favourable outcome. Co-expression of c-erbB-2 and EGFR was associated with a worse prognosis. c-erbB-4 expression, however, showed an antagonistic effect on the clinical influence of c-erbB-2 expression. In conclusion, c-erbB-2 expression in breast carcinomas is associated with an unfavourable clinical course and EGFR expression has a synergistic effect. However, c-erbB-4 antagonizes the c-erbB-2 effect on clinical course in breast carcinomas. To achieve best results with immunotherapy against the c-erbB-2 receptor, clarifying the status of c-erbB-4 expression may be of significance. Copyright (C) 2001 John Wiley Sons, Ltd.